Article
Tumor mutational burden modulates the prognostic effect of RAS mutations in metastatic colon cancer: mechanistic insights and genotype-phenotype correlations.
Journal of translational medicine - 5 Nov 2025
Ianniello Monica, Ottaiano Alessandro, Bocchetti Marco, Ruggiero Raffaella, Santorsola Mariachiara, Sirica Roberto, Caraglia Francesco, Ceccarelli Anna, Toscano Enrica, Picone Carmine, Ciappina Giuliana, Cossu Alessia Maria, Petrillo Nadia, Fico Antonio, Circelli Luisa, Sabbatino Francesco, Barone Antonio, Sperlongano Rossella, Berretta Massimiliano, Caraglia Michele, Savarese Giovanni
Abstract excerpt
BACKGROUND: RAS mutations, present in 40-50% of metastatic colorectal cancer (mCRC) cases, drive oncogenic signaling and confer resistance to anti-EGFR therapies. Tumor mutational burden (TMB), a marker of genomic instability, has recently emerged as a predictive biomarker of response to immunotherapy. However, the prognostic interaction between RAS status and TMB in mCRC remains poorly defined. PATIENTS AND...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
